For the latest quarter, PTC Therapeutics Inc reported the revenue of 151.31M USD for the period ending 2026-06-30, which came from the top-performing segment, Sephience. United States contributed the highest revenue, at 152.18M USD.

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

Non-US

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

United States

1.49B(86.37%)

413.04M(51.20%)

531.66M(56.69%)

498.57M(71.35%)

297.00M(55.14%)

186.40M(48.95%)

116.68M(38.01%)

93.69M(35.39%)

49.16M(25.29%)

1.21M(1.46%)

5.22M(14.19%)

25.25M(100.00%)

34.70M(100.00%)

Non-US

235.89M(13.63%)

393.74M(48.80%)

406.16M(43.31%)

200.23M(28.65%)

241.59M(44.86%)

194.37M(51.05%)

190.30M(61.99%)

171.04M(64.61%)

145.24M(74.71%)

81.50M(98.54%)

31.55M(85.81%)

--(--)